North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market to Reach USD 17.15Bby 2033

North America MASH Therapeutics Market Overview | CAGR 19.3% Growth by 2033

AUSTIN, TX, UNITED STATES, November 12, 2025 /EINPresswire.com/ -- Market Size and Growth

According to DataM Intelligence, the North America metabolic dysfunction-associated steatohepatitis (MASH) treatment market size was valued at US$ 3.70 billion in 2024 and is projected to reach US$ 17.15 billion by 2033, exhibiting a CAGR of 19.3% during the forecast period 2025–2033. Increasing prevalence of obesity, diabetes, and metabolic syndrome is driving demand for innovative MASH therapies in the region.

The growing awareness of MASH as a severe liver disease associated with metabolic dysfunction, coupled with advancements in pharmacological agents targeting inflammation and fibrosis, is fueling market growth. Enhanced diagnostic capabilities and government funding for liver disease research further accelerate therapeutic adoption.

Download PDF Brochure:
https://www.datamintelligence.com/download-sample/north-america-metabolic-dysfunction-associated-steatohepatitis-treatment-market

Browse in-depth TOC on "North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market"

70 – Tables
66 – Figures
195 – Pages

Growth Drivers

• The rising incidence of obesity and diabetes in North America, key risk factors for MASH, has increased the patient pool significantly.

• Advancements in novel drug candidates addressing liver inflammation and fibrosis stages are expanding treatment options.

• Increased government and private sector investment in clinical trials and healthcare infrastructure supports early diagnosis and treatment.

• Rising awareness and adoption of non-invasive diagnostic techniques improve disease management and patient outcomes.

• Growing demand for combination therapies to address complex metabolic pathways driving MASH progression.

Market Segmentation Analysis

By Drug Class
• Anti-inflammatory agents and antifibrotic drugs lead the market, accounting for the majority of revenue in 2024.
• Metabolic regulators and combination therapies are expected to witness the fastest growth during the forecast period.

By End-User
• Hospitals and specialty liver clinics dominate treatment administration, supported by outpatient and research centers focusing on MASH management.

Regional Insights

The U.S. represents the largest market within North America, driven by high obesity rates, well-established healthcare infrastructure, and supportive regulatory frameworks. Canadian markets are also expanding due to increased liver disease screening programs.

Request for Customized Sample Report as per Your Business Requirement:
https://www.datamintelligence.com/customize/north-america-metabolic-dysfunction-associated-steatohepatitis-treatment-market

Competitive Landscape

The North America MASH treatment market is moderately consolidated with key pharmaceutical and biotech players driving innovation. Leading companies include:

Gilead Sciences || Intercept Pharmaceuticals || Novo Nordisk || Allergan, all investing heavily in pipeline development and strategic partnerships.

Recent Developments

• Gilead Sciences advanced its phase 3 clinical trials for novel antifibrotic therapies

• Intercept Pharmaceuticals received FDA fast-track designation for its MASH treatment candidate

• Novo Nordisk initiated combination therapy studies addressing metabolic dysfunction and liver fibrosis

Market Outlook and Opportunities

The North America MASH treatment market is poised for significant growth, driven by rising disease awareness, improved Diagnostic Imaging, and breakthrough therapeutics. Emerging treatment modalities and personalized medicine approaches present substantial opportunities for stakeholders through 2032.

Buy This Report with Year-End Offer (Buy 1 report: Get 30% OFF | Buy 2 reports: Get 50% OFF each! Limited time offer): https://www.datamintelligence.com/buy-now-page?report=north-america-metabolic-dysfunction-associated-steatohepatitis-treatment-market

Conclusion

The North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market is undergoing a transformative phase, expanding rapidly in response to the growing burden of metabolic diseases. Expected to reach USD 5.9 billion by 2032 at a CAGR of 17.6%, the market reflects significant advancements in therapeutic research and clinical adoption. According to DataM Intelligence, key players such as Gilead Sciences, Intercept Pharmaceuticals, and Novo Nordisk are leading efforts to develop efficacious treatments that address the unmet medical needs of MASH patients, heralding a new era in liver disease treatment.

Related Reports:

Non-Alcoholic Fatty Liver Disease (NAFLD) Treatment Market Size to Reach USD 8.4 Billion by 2032 - DataM Intelligence @ https://www.datamintelligence.com/download-sample/nonalcoholic-fatty-liver-disease-market

Global Obesity Therapeutics Market Projected to Expand at 21.6% CAGR through 2032 - DataM Intelligence @ https://www.datamintelligence.com/download-sample/competitive-landscape-of-the-global-obesity-therapeutics-market

Injectable Drug Delivery Market Size to Surpass USD$ 1258.4 by 2032 - DataM Intelligence @ https://www.datamintelligence.com/download-sample/injectable-drug-delivery-market

Pharmacovigilance @ https://www.openpr.com/news/4265577/united-states-pharmacovigilance-market-overview-2025

Sai Kiran
DataM Intelligence 4market Research LLP
+1 877-441-4866
sai.k@datamintelligence.com
Visit us on social media:
LinkedIn
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.